ENTRADA THERAPEUTICS INC. - COMMON STOCK

Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development

24 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire

Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program

06 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire

Entrada Therapeutics Reports Second Quarter 2024 Financial Results

13 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire

Entrada Therapeutics Announces $100 Million Registered Direct Offering

24 июн 2024 07:15:28 Источник Nasdaq GlobeNewswire

Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy

24 июн 2024 06:00:00 Источник Nasdaq GlobeNewswire

Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference

03 июн 2024 07:00:00 Источник Nasdaq GlobeNewswire

Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

16 май 2024 07:00:00 Источник Nasdaq GlobeNewswire

Entrada Therapeutics Reports First Quarter 2024 Financial Results

07 май 2024 07:00:01 Источник Nasdaq GlobeNewswire

Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

13 мар 2024 07:00:00 Источник Nasdaq GlobeNewswire

Entrada Therapeutics to Present at Upcoming Investor Conferences

07 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire

Entrada Therapeutics Promotes Nathan J. Dowden to President

03 янв 2024 07:00:00 Источник Nasdaq GlobeNewswire

Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy

22 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire

Entrada Therapeutics Reports Third Quarter 2023 Financial Results

07 ноя 2023 07:00:01 Источник Nasdaq GlobeNewswire

Entrada Therapeutics to Present at Upcoming Investor Conferences

12 окт 2023 07:00:00 Источник Nasdaq GlobeNewswire

Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy

21 сен 2023 07:00:00 Источник Nasdaq GlobeNewswire

Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community

07 сен 2023 07:00:00 Источник Nasdaq GlobeNewswire

Entrada Therapeutics to Present at Upcoming Investor Conferences

29 авг 2023 07:00:00 Источник Nasdaq GlobeNewswire

Entrada Therapeutics Appoints Gina Chapman to its Board of Directors

10 авг 2023 07:00:00 Источник Nasdaq GlobeNewswire

Entrada Therapeutics Reports Second Quarter 2023 Financial Results

08 авг 2023 07:00:01 Источник Nasdaq GlobeNewswire

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy

01 авг 2023 07:00:00 Источник Nasdaq GlobeNewswire